By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New contraceptive pill linked to lighter and shorter periods

A combined oral contraceptive containing a new hormone combination has been launched in the UK.

The pill branded as Zoely is a combination of nomegestrol acetate 2.5mg and 17ß-estradiol 1.5mg (NOMAC/E2).  

NOMAC/E2 contains a monophasic combination of two hormones: nomegestrol acetate, a highly selective progesterone-derived progestogen that has a 46-hour half-life, and 17ß-estradiol, an oestrogen that is structurally identical to endogenous human 17ß-estradiol.

The combination of contraceptive hormones is delivered through a 24-day active tablet and four-day placebo tablet dosing regimen.

According to trial data, it is associated with withdrawal bleeds of shorter duration and lighter intensity than a combination containing 3mg drospirenone and 30μg ethinylestradiol (DRSP/EE).

However, trials also revealed that 51.2% of women receiving NOMAC/E2 experienced adverse events compared to 37% of women randomised to DRSP/EE.

The most frequently reported NOMAC/E2 adverse events were acne, irregular withdrawal bleeding, increased weight and headache.

The product is manufactured by the pharmaceutical giant MSD.

Readers' comments (2)

  • Best to avoid the pill altogether.

    Unsuitable or offensive?

  • it can take a very long time before the full impact of the side effects are discovered, when is often too late.

    Unsuitable or offensive?

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!